Sterling Capital Management LLC Has $7.83 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Sterling Capital Management LLC lifted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 19.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 56,850 shares of the biotechnology company's stock after purchasing an additional 9,065 shares during the period. Sterling Capital Management LLC owned about 0.09% of Ascendis Pharma A/S worth $7,827,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ASND. FIL Ltd raised its stake in shares of Ascendis Pharma A/S by 13.9% during the 4th quarter. FIL Ltd now owns 729,275 shares of the biotechnology company's stock worth $100,399,000 after acquiring an additional 89,016 shares in the last quarter. American Century Companies Inc. grew its stake in Ascendis Pharma A/S by 17.5% during the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock worth $56,072,000 after buying an additional 60,548 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in shares of Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after acquiring an additional 39,309 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Ascendis Pharma A/S by 94.4% in the 4th quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock worth $10,659,000 after purchasing an additional 37,593 shares in the last quarter. Finally, abrdn plc increased its stake in Ascendis Pharma A/S by 18.3% during the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after purchasing an additional 28,967 shares in the last quarter.

Ascendis Pharma A/S Stock Up 2.4 %

NASDAQ:ASND traded up $3.74 during trading hours on Thursday, reaching $161.89. The company had a trading volume of 182,552 shares, compared to its average volume of 477,525. The firm has a market capitalization of $9.87 billion, a PE ratio of -22.80 and a beta of 0.54. The stock has a 50-day moving average of $150.17 and a two-hundred day moving average of $137.96. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

ASND has been the subject of several research analyst reports. The Goldman Sachs Group raised their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research report on Tuesday, February 18th. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 25th. Finally, Royal Bank of Canada initiated coverage on Ascendis Pharma A/S in a report on Wednesday. They issued an "outperform" rating and a $205.00 price objective on the stock. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.